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Regular Article
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Defective TAFI activation in hemophilia A mice is a major
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KEY PO INT S
l Degree of TAFI
activation in HA is a
modiﬁer of hemophilic
joint bleeding that
inversely affects
bleeding severity.
l Defective TAFI
activation in severe
congenital HA impairs
protection against
uPA-mediated
ﬁbrinolysis in bleeding
joints.
Joint bleeds are common in congenital hemophilia but rare in acquired hemophilia A (aHA) for
reasons unknown. To identify key mechanisms responsible for joint-speciﬁc bleeding in con-
genital hemophilia, bleeding phenotypes after joint injury and tail transection were compared
in aHA wild-type (WT) mice (receiving an anti–factor VIII [FVIII] antibody) and congenital HA
(FVIII2/2) mice. Both aHA and FVIII2/2 mice bled severely after tail transection, but consistent
with clinical ﬁndings, joint bleeding was notably milder in aHA compared with FVIII2/2 mice.
Focus was directed to thrombin-activatable ﬁbrinolysis inhibitor (TAFI) to determine its po-
tentially protective effect on joint bleeding in aHA. Joint bleeding in TAFI2/2micewith anti-FVIII
antibody was increased, compared with WT aHA mice, and became indistinguishable from
joint bleeding in FVIII2/2 mice. Measurements of circulating TAFI zymogen consumption
after joint injury indicated severely defective TAFI activation in FVIII2/2 mice in vivo,
consistent with previous in vitro analyses in FVIII-deﬁcient plasma. In contrast, notable TAFI
activation was observed in aHA mice, suggesting that TAFI protected aHA joints against
bleeding. Pharmacological inhibitors of ﬁbrinolysis revealed that urokinase-type plasmino-
gen activator (uPA)–induced ﬁbrinolysis drove joint bleeding, whereas tissue-type plasminogen activator–mediated ﬁ-
brinolysis contributed to tail bleeding. These data identify TAFI as an importantmodiﬁer of hemophilic joint bleeding in aHA
by inhibiting uPA-mediated ﬁbrinolysis. Moreover, our data suggest that bleed protection by TAFI was absent in congenital
FVIII2/2micebecauseof severelydefective TAFI activation, underscoring the importanceof clot protection in addition to clot
formation when considering prohemostatic strategies for hemophilic joint bleeding. (Blood. 2018;132(15):1593-1603)
Introduction
Patients with severe factor VIII (FVIII) or FIX deﬁciency (hemo-
philia A [HA] or B) experience frequent joint bleeding that results
in hemophilic joint disease, a major cause of joint deterioration
and disability in the hemophilia population.1 Joint bleeds ac-
count for ;70% of total bleeds in patients with severe hemo-
philia (factor levels ,1%), with the incidence of joint bleeds
generally increasing with the severity of FVIII or FIX deﬁciency.
Factor replacement therapy limits the incidence of joint bleeds
to a certain degree but cannot prevent the progression of he-
mophilic joint disease, even when prophylaxis is initiated very
early in life.2-4 Furthermore, the development of inhibitory al-
loantibodies in ;30% of patients with hemophilia complicates
lifelong factor replacement therapy and increases susceptibility
to frequent joint bleeds.5
Unlike in congenital hemophilia, joint bleeding is uncommon in
acquired HA (aHA), a rare autoimmune disease, in which auto-
antibodies are produced against certain epitopes on endogenous
FVIII, and these type 2 inhibitors typically do not accomplish full
inhibition of FVIII.6 This divergent clinical bleeding pattern pro-
vides unique opportunities to interrogate the key mechanism(s)
responsible for joint-speciﬁc bleeding in congenital HA. Such
mechanismsmay extendwell beyond the initial clot formation and
involve factors that modulate vascular bed–speciﬁc clot stability
and/or ﬁbrinolysis.
One potential candidate for modulation of clot stability and ﬁ-
brinolysis is thrombin-activatable ﬁbrinolysis inhibitor (TAFI;
gene CPB2).7,8 Activated TAFI (TAFIa) inhibits ﬁbrinolysis by
removing C-terminal Lys residues on partially degraded ﬁbrin,
which serve as a cofactor for plasminogen activation by tissue-
type plasminogen activator (tPA) or urokinase-type plasminogen
activator (uPA).9-11 It is generally recognized that bleeding is
precipitated in hemophilia by defective thrombin generation in
tissues with relatively low tissue factor expression, such as the
joints.12 Hemophilic clots in these tissues are fragile and sus-
ceptible to premature degradation by the ﬁbrinolytic system.13
At least in vitro, defective TAFI activation in hemophilia has been
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shown to enhance ﬁbrinolysis, resulting in poor clot stability and
premature lysis.14-16 Relatively abundant thrombin is required
for TAFI activation that is normally generated by thrombin-
mediated FXI activation and feedback via the intrinsic path-
way.17 TAFI activation is defective in hemophilia plasma in vitro
because this intrinsic feedback loop for thrombin generation is
inoperable in hemophilia, especially at low tissue factor levels.
However, the activation of TAFI and TAFIa-mediated inhibition
of ﬁbrinolysis are relatively unaffected in the presence of an
inhibitory anti-FVIII antibody in normal plasma, even at antibody
concentrations that severely affect clotting.18 Therefore, the
susceptibility of TAFI activation to residual levels of FVIII pro-
vides a notable distinction between acquired and congenital
hemophilia in clot lysis assays in vitro.
Our understanding of the physiological and pathophysiological
activation mechanisms of TAFI in various vascular beds in vivo
remains limited, and the extent to which the activation of TAFI in
hemophilia in vivo is defective remains undetermined. This de-
termination is convoluted by the fact that thrombomodulin en-
hances thrombin-mediated TAFI activation by approximately
1000-fold.19,20 Consequently, TAFI activation in the presence of
thrombomodulin proceeds efﬁciently in hemophilia plasma even
at low tissue factor concentrations.21 Thrombomodulin is readily
detected on the synovial lining of the joint.22,23 The degree of TAFI
activation in hemophilic joints is therefore conceivably dependent
on the vascular bed–speciﬁc contribution of thrombomodulin.
To elucidate the potential contribution of TAFI in conjunction
with vascular bed–speciﬁc factors to hemophilic joint bleeding,
we adopted a joint injury model in FVIII2/2 mice to induce joint
bleeding.24 The joint injury model is distinctive from other fre-
quently used acute bleeding models in hemophilia (eg, tail clip
or saphenous vein puncture25) in that bleeding occurs slowly
over several days into the microvascularized intra- and peri-
articular tissues. Comparing bleeding characteristics of the joint
bleeding model with those of an acute bleeding model, such as
tail transection, may help to discern time-dependent and vas-
cular bed–speciﬁc contributions to the complex mechanisms of
hemophilic joint and soft tissue bleeding.
Here, we aimed to identify key factors involved in joint-speciﬁc
bleeding in HA by comparing the bleeding phenotype of ac-
quired vs congenital FVIII deﬁciency in mice. We hypothesized
that impaired generation of TAFIa in severe congenital hemo-
philia underlies joint bleeding and, conversely, that residual
TAFI activation occurring in acquired hemophilia protects
against joint bleeding.
Materials and methods
Additional details can be found in the supplemental Information,
available on the Blood Web site.
Animals
All animal protocols were approved by the institutional animal
and care committee of The Scripps Research Institute. FVIII2/2
mice on a BALB/c background26 were a generous gift from
Dr David Lillicrap (Queen’s University, Kingston, Ontario, Canada).
TAFI2/2 mice on a C57Bl/6J background were generated
as described.27 Wild-type (WT) BALB/c and WT C57Bl/6J mice
were obtained from the Scripps Research Institute internal
breeding facility. Skeletally mature mice (age 12-16 weeks) of
both sexes were used for joint bleeding assays, and mice (age
8-12 weeks) of both sexes were used for tail bleeding assays.
Joint and tail bleeding assays
Bleeding in themouse right knee jointwas inducedby a subpatellar
puncture using a 30-G needle as described.28 Bleeding was de-
termined by hematocrit (Hct) 2 days after the injury as described.29
Tail bleeding assays were performed as described.30
Determination of TAFI activation in plasma
TAFI activation in vivo was determined by the extent of TAFI
zymogen consumption. TAFI zymogen levels were determined
in mouse plasma samples using immunoprecipitation and im-
munoblot analyses.31
Treatments
Two hours before joint injury or tail resection, mice were injected
retroorbitally with inhibitory anti-FVIII antibody GMA-801518,32
(0.25-1 mg/kg; Green Mountain Antibodies, Burlington, VT),
inhibitory anti-TAFI antibody MA-RT36A3F533 (destabilizing
TAFIa; 7.5 mg/kg) or MA-TCK26D634,35 (inhibiting thrombin- and
plasmin-mediated activation of TAFI and also interfering with
TAFIa binding to ﬁbrin; 3.75 mg/kg), or an inhibitory anti-uPA
antibody (mU1; 10 mg/kg)36 diluted in sterile saline (0.9%;
Hospira Inc.). Tranexamic acid (TXA; Acros Organics) was ad-
ministered in the drinking water as described.37 uPA inhibitor
amiloride (Sigma Aldrich) was administered subcutaneously using
an osmotic pump (Alzet #2001) at a rate of 4 mg/kg per day.
Statistical analysis
Kruskal-Wallis test followed by Dunn’s post hoc multiple com-
parison test for in vivo data or 1-way analysis of variance followed
by Dunnett’s post hoc multiple comparison test for thrombin
generation and clot lysis data were used to determine statistical
signiﬁcance using GraphPad Prism (San Diego, CA). Survival
curves were graphed using the Kaplan-Meier method, and
statistical signiﬁcance was determined by the log-rank (Mantel-Cox)
test. Correlations were analyzed using the Pearson correlation test.
A P value of ,.05 was considered statistically signiﬁcant. Data
are expressed as mean 6 standard deviation.
Results
Differences in joint bleeding susceptibility between
aHA vs congenital HA mouse models
Joint injury in FVIII2/2 BALB/c mice caused considerable joint
bleeding, as evidenced by a decrease in Hct 2 days after injury
(day 2 [D2] Hct, 29% 6 11% vs baseline Hct, 47% 6 2%;
P, .0001; Figure 1A), and was consistent with previous studies.24,38
Inhibitory anti-FVIII antibody GMA-8015 was used to induce
aHA. A GMA-8015 dose of 0.25 mg/kg in WT BALB/c mice,
corresponding to 35 BU/mL at 2 hours after injection, was
previously shown to increase tail bleeding to the same extent as
in FVIII2/2 BALB/c mice.18 Also, similar tail bleeding was ob-
served when the inhibitory anti-FVIII antibody was administered
toWTC57Bl/6Jmice (Figure 2A-C), indicating that there were no
apparent differences between C57Bl/6J and BALB/c strains,
although FVIII2/2C57BL/6Jmice were not tested. However, only
minimal joint bleeding was observed in anti-FVIII antibody–
treated WT C57Bl/6J mice (D2 Hct, 40% 6 4%; Figure 1A) or
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anti-FVIII antibody–treatedWT BALB/cmice (D2 Hct, 44%6 4%;
supplemental Figure 1). Increasing the anti-FVIII antibody dos-
age to 1 mg/kg in C57Bl/6J mice resulted in signiﬁcant joint
bleeding (D2 Hct, 36% 6 9%; P , .05); however, bleeding
remained considerably less severe than observed in FVIII2/2
mice (Figure 1A). Weight-bearing impairment of the injured hind
leg was measured as a functional consequence of joint bleeding
based on its inverse correlation with D2 Hct (P , .0001; r 5 20.80;
supplemental Figure 2). Consistent with less severe bleeding, anti-
FVIII antibody–treated WT mice showed impaired but non-
signiﬁcant imbalanced weight bearing compared with baseline
(Figure 1B). In contrast, the weight-bearing ratio was signiﬁcantly
impaired in injured FVIII2/2mice (Figure 1B). Thus, the joint injury
model recapitulates the clinically observed discrepancy in joint
bleeding susceptibility between patients with congenital HA and
those with aHA.
No susceptibility differences in tail bleeding
between aHA and congenital HA mouse models
Unlike with reduced susceptibility to joint bleeding, GMA-8015
anti-FVIII antibody–treated WT mice demonstrated no suscep-
tibility difference compared with FVIII2/2 mice in acute tail
bleeding. Blood loss volumes in anti-FVIII antibody–treated WT
C57Bl/6J (Figure 2A) and WT BALB/c18 mice were similar to
those in FVIII2/2 BALB/c mice after tail resection (Figure 2B).
Several controls were performed to ensure that experimental
factors (eg, differences in the timeframe and analysis methods
for bleeding) were not responsible for the observed difference in
the susceptibility to joint and tail bleeding. First, the clearance
rate of GMA-8015 was determined. When administered at 0.25
mg/kg, the antibody increased tail bleeding up to 3 days after
injection to levels similar to those observed in FVIII2/2 mice
(Figure 2A), thus ruling out that loss of FVIII inhibition could be
responsible for reduced joint bleeding in aHA mice. Second, a
GMA-8015 dose-response titration demonstrated that FVIII2/2
like tail bleeding was induced from $0.0625 mg/kg of GMA-
8015, indicating that the 0.25-mg/kg dose was well within the
GMA-8015 dosing range that caused signiﬁcant inhibition of
coagulation. Finally, Hct was determined after tail resection to
compare tail bleeding with joint bleeding using the same end
point measurement. Hct at 24 hours was found to be inversely
correlated with acute blood loss after 20 minutes (P , .0001;
r 5 20.73; supplemental Figure 3). For example, GMA-8015 at
0.25 mg/kg, which caused similar acute blood loss after tail
resection in WT compared with FVIII2/2 mice (Figure 2B), also
reduced Hct at 24 hours to a similar extent (20%6 8% vs 19%6
1%; Figure 2C). At 0.0625 mg/kg, however, acute blood loss was
still maximal, whereas Hct at 24 hours was intermediate (27% 6
3% vs 37% 6 7%), indicating fewer rebleeding events. This
dosage-dependent effect at 24 hours could not be explained by
the ex vivo APTT that was maximally prolonged at 0.0625 mg/kg
(supplemental Figure 4A). In contrast, dose-dependent differ-
ences did arise in ex vivo thrombin generation, with 0.25 mg/kg
of antibody having a signiﬁcant impact (reduced endogenous
thrombin potential and peak height), whereas 0.0625 mg/kg did
not (Figure 2D-G). Thus, GMA-8015 at a dosage of 0.25 mg/kg
provided a prolonged impairment of coagulation sufﬁcient to
increase tail bleedingmaximally, but not joint bleeding. Unlike in
FVIII2/2 mouse plasma, injection of GMA-8015 (#1 mg/kg) did
not impair the TAFIa-mediated attenuation of clot lysis in WT
plasma (Figure 2H-I; supplemental Figure 4B-C), suggesting that
residual thrombin formation in aHA mice leads to sufﬁcient
activation of TAFI and results in a prohemostatic effect in the
joints after injury.
TAFI protects against joint bleeding in aHA
To probe a potential role for TAFI in joint bleeding, the aHA
model was applied to TAFI2/2 mice. Administration of anti-FVIII
antibody GMA-8015 (0.25 mg/kg) in TAFI2/2 mice resulted in
signiﬁcant joint bleeding that was markedly increased compared
with that in anti-FVIII antibody–treated WT mice (D2 Hct, 25%6
8% vs 41% 6 3%; P , .0001; Figure 3A). Visual inspection in-
dicated that hematomas in anti-FVIII antibody–treated TAFI2/2
mice were similar to those in FVIII2/2 mice and were larger
and darker (blood ﬁlled) compared with those in anti-FVIII
antibody–treated WT mice (Figure 3B). Increased joint bleed-
ing in WT mice when the anti-FVIII antibody was coadministered
with an inhibitory antibody against TAFI (MA-RT36A3F533) fur-
ther conﬁrmed that joint bleeding increased upon impaired
TAFIa function (D2 Hct, 34% 6 7%; P , .01; Figure 3A). Similar
results were obtained when the inhibitory anti-FVIII and anti-
TAFI antibodies were coadministered in WT BALB/c mice, in-
dicating that there were no apparent differences between
C57Bl/6J and BALB/c strains (supplemental Figure 5). Histological
analysis demonstrated presence of extravasated erythrocytes and
local inﬂammation-induced hypercellularity in the joint space of
FVIII2/2mice 7 days after injury (Figure 3C). This was associatedwith
the expansion of the synovial and stromal linings (Figure 3D).
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Figure 1. aHAmice are protected against joint bleeding after
injury. (A) Joint bleeding after knee injury in WT C57Bl/6J mice
(n 5 9-12; ﬁlled squares) that received different doses of the
inhibitory anti-FVIII antibody (0-1 mg/kg; GMA-8015). Bleeding
was determined bymeasuring Hct at day 2 (D2) postinjury. D2 Hct
values for injured FVIII2/2 BALB/c mice (n 5 9; ﬁlled circles) are
shown to illustrate typical joint bleeding in congenital HA mice.
Hct ofWTC57Bl/6J (open square) or FVIII2/2 BALB/c (open circle)
mice at baseline (BL; no injury) are provided as a no-bleeding
reference (n5 8-10). (B) Weight-bearing ratio of left (uninjured) vs
right (injured) hind paw at BL (n 5 5) and at D2 after right knee
injury in WT C57Bl/6J (n 5 6) or FVIII2/2 BALB/c (n 5 4) mice at
the indicated doses (mg/kg) of anti-FVIII antibody. Kruskal-
Wallis test followed by Dunn’s post hoc multiple comparison
test was used to compare experimental mice with WT mice at
baseline. BL indicates baseline without knee injury; injured in-
dicates right knee injury. **P , .01, ****P , .0001. ns, not
signiﬁcant.
DEFECTIVE TAFI ACTIVATION IN HEMOPHILIA A blood® 11 OCTOBER 2018 | VOLUME 132, NUMBER 15 1595
For personal use only.on January 29, 2019. by guest  www.bloodjournal.orgFrom 
***
***
***
*
B
0.00
0
10
20
30
40
50
Anti-FVIII antibody (mg/kg)
Bl
oo
d 
lo
ss
 (
L/
g)
0.25 0.50 0.75 1.00
*
ns
*
**
E
0.
00
 m
g
/k
g
0.
06
 m
g
/k
g
0.
25
 m
g
/k
g
1.
00
 m
g
/k
g
FV
III
 K
O
0
200
400
600
800
1000
Anti-FVIII antibody
(mg/kg)
ET
P 
(n
M
*m
in
ut
es
)
H
0
0.5
0.6
0.7
0.8
0.9
5 10
Time (min)
15 20 25 30
OD
40
5n
m
WT-anti-FVIII Ab
WT FVIII-/-
***
****
****
**
C
0.00
0
10
20
30
40
50
Anti-FVIII antibody (mg/kg)
Hc
t (
%
) a
t 2
4 
ho
ur
s
0.25 0.50 0.75 1.00
ns
*
*
**
F
0.
00
 m
g
/k
g
0.
06
 m
g
/k
g
0.
25
 m
g
/k
g
1.
00
 m
g
/k
g
FV
III
 K
O
0
20
40
60
100
80
120
140
Anti-FVIII antibody
(mg/kg)
Pe
ak
 h
ei
gh
t (
nM
)
ns
ns ns
**
I
0.
00
 m
g
/k
g
0.
06
 m
g
/k
g
0.
25
 m
g
/k
g
1.
00
 m
g
/k
g
FV
III
-/
-
0
5
10
15
20
25
30
Anti-FVIII antibody
(mg/kg)
CL
T 5
0%
 (m
in
)
0
0
10
20
30
40
50 ****
ns
ns
A
1 2
Time post injection (days)
Bl
oo
d 
lo
ss
 (
L/
g)
3 4 5 6 7
D
0
0
20
40
60
80
100
120 0.00 mg/kg
0.06 mg/kg
0.25 mg/kg
1.00 mg/kg
FVIII KO
5
Time (min)
Th
ro
m
bi
n 
(n
M
)
10 15 20
ns
ns
ns
**
G
0.
00
 m
g
/k
g
0.
06
 m
g
/k
g
0.
25
 m
g
/k
g
1.
00
 m
g
/k
g
FV
III
-/
-
0
2
4
6
8
10
Anti-FVIII antibody
(mg/kg)
T T
P 
(m
in
)
Figure 2. aHA mice are not protected against tail bleeding. (A) Tail bleeding in WT C57Bl/6J mice at different time points after injection of anti-FVIII antibody (0.25 mg/kg;
n 5 4-5). Bleeding was determined by measuring the mouse weight-normalized blood loss (mL/g) after tail resection for 20 minutes. (B) Tail bleeding in WT C57Bl/6J mice
(n5 5-10; ﬁlled circles) measured 2 hours after injection of different doses of anti-FVIII antibody (0-1 mg/kg). Tail bleeding in FVIII2/2 BALB/c mice (n5 8; open circle) is shown as
reference. (C) Bleeding determined by Hct at 24 hours after tail resection inWT C57Bl/6J mice (n5 5-10; ﬁlled circles) injected with different doses of anti-FVIII antibody (0-1 mg/
kg). Hct at 24 hours in FVIII2/2 BALB/c mice (n5 8; open circle) after tail resection is shown as reference. Representative thrombin-generation proﬁles (D), endogenous thrombin
potential (ETP; nM3minutes) (E), peak height (nM) (F), and time to peak (TTP; minutes) (G) of plasma samples taken 24 hours after injection of anti-FVIII antibody (0-1 mg/kg) in
WT BALB/c mice (n5 3-4 per antibody dosage) or FVIII2/2 BALB/cmice (n5 3). (H) Representative uPA-mediated plasma clot lysis proﬁles from a FVIII2/2 BALB/cmouse (red) or
WT BALB/c mouse injected 24 hours before with either saline (blue) or anti-FVIII antibody (0.25 mg/kg; green). The 50% clot lysis time (CLT50%), representing the time between
maximal clot formation and half-maximal clot lysis, is indicated by arrows. (I) CLT50% (minutes) of plasma samples taken 24 hours after injection of anti-FVIII antibody (0-1 mg/kg) in
WT BALB/c mice (n5 3-4 per antibody dosage) or FVIII2/2 BALB/c mice (n5 3). Thrombin-generation and clot lysis data are the mean of 2 independent experiments for each
sample. Kruskal-Wallis test followedbyDunn’s post hocmultiple comparison test (A-C) or 1-way analysis of variance followed byDunnett’s post hocmultiple comparison test (D-I) was used
to compare experimental mice with WT mice injected with saline. *P , .05, **P , .01, ***P , .001, ****P , .0001. KO, knockout; ns, not signiﬁcant; OD, optical density.
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Extravasation of erythrocytes was minimal in anti-FVIII antibody–
treatedWTmice, and although at day 4, some soft tissue expansion
was observed in the joints of these mice, the extent of tissue ex-
pansion normalized at day 7 (Figure 3C-D). Coinciding with ex-
posure to increased blood volumes, soft tissue expansion was
overall increased inWTmice receiving both anti-FVIII and anti-TAFI
antibodies and in anti-FVIII antibody–treated TAFI2/2 mice
(Figure 3C-D). Furthermore, the anti-TAFI antibody did not
have an additional effect on joint bleeding or soft tissue expansion
in FVIII2/2 mice (supplemental Figure 6), suggesting that TAFI is
indeed not being activated in hemophilia. Collectively, these data
indicate that residual TAFI activation in aHA protects against
extensive joint bleeding.
Defective TAFI activation in HA mice in vivo
The ability of TAFI to protect against extensive joint bleeding in
aHA raised the question of whether the pronounced joint
bleeding observed in the congenital HA mouse injury model
resulted from defective TAFI activation. The extent of TAFI
activation after knee injury was determined in plasma obtained
from injured aHA WT mice and FVIII2/2 mice by measuring
zymogen consumption, as compared with the respective
baseline levels. After injury, TAFI activation (inferred from the
disappearance of TAFI zymogen) was detectable in anti-FVIII
antibody–treatedWTmice but not in FVIII2/2mice (Figure 4A-B).
Treatment of FVIII2/2 mice with recombinant human FVIII
resulted in very low plasma zymogen TAFI levels after joint injury,
indicating that the TAFI zymogen was almost completely con-
sumed after FVIII administration. These in vivo data conﬁrm im-
portant previous assumptions derived from in vitro studies,14,15
namely that TAFI activation in vivo is severely impaired upon joint
injury with congenital FVIII deﬁciency. In contrast, notable TAFI
activation remains detectable in acquired hemophilia.
To determine the mechanism of TAFI activation in aHAWT mice
after injury, the inhibitory anti-TAFI antibody MA-TCK26D634
was used. This antibody blocks thrombin- and plasmin-mediated
TAFI activation, but not thrombin-thrombomodulin–mediated
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antibody–treatedWT-C57Bl/6J or TAFI2/2 C57Bl/6J mouse. (C) Representative images of Safranin-O fast green staining of the left uninjured knee joint and corresponding right
injured knee joint harvested at day 7 postinjury of a WT C57Bl/6J or TAFI2/2 C57Bl/6J mouse injected with anti-FVIII antibody (0.25 mg/kg) or of a FVIII2/2 BALB/c mouse. The
yellow line indicates soft tissue expansion between the anterior meniscus and joint capsule. Original magniﬁcation, 34; scale bar 5 200 mm. (D) Soft tissue expansion (mm) at
baseline (BL) and days 4 and 7 postinjury inWTC57Bl/6J, TAFI2/2C57Bl/6J, and FVIII2/2 BALB/cmice with and without anti-FVIII antibody (0.25mg/kg) and/or anti-TAFI antibody
(MA-RT36A3F5; 7.5 mg/kg; n5 4-6). Soft tissue expansion was measured as the distance between the anterior meniscus and joint capsule (indicated by the yellow line in Figure
3C). BL indicates baseline without knee injury. Kruskal-Wallis test followed by Dunn’s post hoc multiple comparison test was used to compare experimental mice with their
respective baseline controls. *P , .05, **P , .01, ***P , .001, ****P , .0001. ns, not signiﬁcant.
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TAFI activation.19,20 TAFI zymogen levels were largely retained
after injury in the presence of MA-TCK26D6, indicating that
inhibition of thrombin- and/or plasmin-mediated TAFI activation
prevented the consumption of TAFI zymogen after joint injury in
FVIII2/2 mice (Figure 4A-B). This excludes the thrombin-
thrombomodulin complex as the main activator of TAFI after
joint injury under these conditions. Furthermore, the virtually
complete consumption of TAFI zymogen with recombinant
human FVIII treatment points to a primary role for thrombin-
mediated as opposed to plasmin-mediated TAFI activation after
joint injury. Increased thrombin-antithrombin levels in aHA mice
with anti-TAFI antibody compared with those in FVIII2/2 mice
also support added generation of thrombin in aHA to activate
TAFI (supplemental Figure 7). It should be noted that TAFI is an
acute-phase reactant in mice.39,40 Hence, TAFI levels may have
risen above baseline with injury-induced bleeding, potentially
masking partial activation by thrombin-thrombomodulin in the
presence of MA-TCK26D6 sufﬁcient for bleed protection.
However, MA-TCK26D6 did increase joint bleeding in anti-FVIII
antibody–treated WT mice (D2 Hct, 30% 6 5%; P , .05 vs
baseline; supplemental Figure 8), similar to MA-RT36A3F5
(accelerating the inactivation rate of TAFIa; Figure 3A).
MA-TCK26D6 is also capable of blunting the antiﬁbrinolytic
effect of TAFIa directly35; therefore, a potential contribution
of TAFI activation by the thrombin-thrombomodulin complex
cannot be formally excluded.
Vascular bed–speciﬁc contributions of TAFI
deﬁciency to bleeding in HA
In agreement with previous studies, TAFI2/2 mice did not
demonstrate increased bleeding compared with WT mice within
20 minutes after tail resection (Figure 5A).16,41,42 Also, TAFI
deﬁciency did not aggravate acute bleeding after tail resection
in the presence of the anti-FVIII antibody (Figure 5A), suggesting
that TAFI deﬁciency does not further increase rapid bleeding
from the tail vasculature in aHA. To incorporate potential effects
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TAFI levels 2 days after injury by immunoblot after pull down in
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(200 IU/kg) or in WT mice with anti-FVIII antibody (GMA-8015;
0.25 mg/kg) alone (n 5 9) or in combination with anti-TAFI
antibody (MA-TCK26D6; 3.75 mg/kg; n 5 4). Kruskal-Wallis
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Figure 5. TAFI deﬁciency does not cause prolonged tail bleeding in HAmice. (A) Tail bleeding in WT C57Bl/6J, TAFI2/2 C57Bl/6J, and FVIII2/2 BALB/c mice with or without
anti-FVIII antibody (0.25mg/kg; n5 8-12). Bleeding was determined bymeasuring themouse weight-normalized blood loss (mL/g) after tail resection for 20minutes. (B) Bleeding
determined by Hct at 24 hours after tail resection in WT C57Bl/6J, TAFI2/2 C57Bl/6J, and FVIII2/2 BALB/c mice, with or without anti-FVIII antibody (0.25 mg/kg), that survived 24
hours after tail resection. (C) Survival rate after tail resection ofWTC57Bl/6J (n5 12; ﬁlled and open down triangles) or TAFI2/2C57Bl/6J (n5 12; ﬁlled and open up triangles) with
(open triangles) or without (ﬁlled triangles) anti-FVIII antibody (0.25 mg/kg) and FVIII2/2 BALB/c mice (n5 8; open circles). For the survival experiment, the log-rank (Mantel-Cox)
test was used to compare experimental mice with WT mice after tail clip. Kruskal-Wallis test was used followed by Dunn’s post hoc multiple comparison test to compare
experimental mice. *P , .05, **P , .01, ***P , .001. ns, not signiﬁcant.
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of TAFI on rebleeding events, Hct was measured 24 hours after
tail resection as a surrogate measure for delayed bleeding. TAFI
deﬁciency had no effect on Hct levels (Figure 5B). Because Hct at
24 hours only represented survivors, 24-hourmortality rates were
determined. The 24-hour mortality rate was signiﬁcantly increased
from 0% to 50% in FVIII2/2 mice and to 33% in anti-FVIII
antibody–treated WT mice. TAFI deﬁciency caused no additional
effects onmortality 24 hours after tail resection (Figure 5C; Table 1).
Therefore, in contrast to the observed increased bleeding after
joint injury, TAFI deﬁciency did not increase bleeding after
tail resection in mice treated with anti-FVIII antibody, indicating
that the TAFI-mediated effects on bleeding were vascular bed
speciﬁc and were of particular importance to the intra- and
periarticular sites of the knee joints.
Differential effects of antiﬁbrinolytic drugs on joint
vs tail bleeding
Antiﬁbrinolytic drug TXA was tested for its potential effects on
joint bleeding to gain insight into the mechanism responsible for
the ability of TAFIa to protect against joint bleeding in aHA. As a
Lys analog, TXA impedes plasminogen binding to partially
degraded ﬁbrin. However, TXA did not correct injury-induced
joint bleeding in either FVIII2/2 mice (Figure 6A) or anti-FVIII
antibody–treated TAFI2/2 mice (Figure 6B). In contrast, TXA did
correct tail bleeding in FVIII2/2mice (Figure 6C-D) and anti-FVIII
antibody–treated WT mice (supplemental Figure 9), indicating
that the TXA dosing used conveyed effective antiﬁbrinolytic
activity, thereby eliminating suboptimal dosing as a possible
cause for the failure of TXA to inhibit joint bleeding.
In addition to impeding plasminogen binding to ﬁbrin and
enhancing clot stability, TXA also considerably augments the
ability of uPA to activate plasminogen, independent of ﬁbrin,
thereby increasing ﬁbrinolysis.11,43,44 This dual role of TXA may
explain its ineffectiveness in bleed reduction in inﬂamed tissues
with high uPA expression such as in the synovial joint after
bleeding.45,46 To probe a potential contribution of uPA-
mediated activation of ﬁbrinolysis to joint bleeding, uPA in-
hibitors were tested: amiloride, which is a clinically available
antihypertensive molecule but also a potent inhibitor of uPA,
and inhibitory anti-uPA antibody mU1.36 Amiloride reduced joint
bleeding in FVIII2/2mice and anti-FVIII antibody–treated TAFI2/2
mice signiﬁcantly (Figure 6A-B). Antibody-mediated uPA
blockade conﬁrmed the contribution of uPA-induced plasmin
formation to hemophilic joint bleeding (Figure 6A-B), because
the antibody reduced joint bleeding in FVIII2/2mice (D2Hct, 35%6
10% vs 25% 6 10%; P , .05; Figure 6A) and anti-FVIII antibody–
treated TAFI2/2 mice (D2 Hct, 36% 6 9% vs 26% 6 8%; P , .01;
Figure 6B). In contrast, neither amiloride nor the anti-uPA antibody
reduced hemophilic tail bleeding (Figure 6C-D). Although these data
suggest a uniform contribution of ﬁbrinolysis to bleeding, either
after joint injury or tail resection, the difference in the plasminogen
activators responsible for initiation of ﬁbrinolysis (uPA in the joint
but not in the tail and tPA in the tail) emphasizes differential
vascular bed–speciﬁc contributions of plasminogen activators.
Discussion
The different bleeding diathesis of congenital and acquired he-
mophilias is clinically well recognized but mechanistically poorly
understood.6,47,48 Reproducing a notably milder joint injury–
induced bleeding phenotype in aHA WT mice compared with
FVIII2/2 mice provided a clinically relevant model to unravel he-
mostatic mechanisms speciﬁc to the joints. As opposed to the
mild joint bleeding in aHA mice, tail bleeding was severe, in-
dicating that aHA compromises coagulation in vivo severely. This
ﬁnding is in agreement with the ex vivo effect of the anti-FVIII
antibody in mouse plasma shown here and in normal human
plasma in vitro.18 The joint-speciﬁc protection against bleeding in
the presence of the anti-FVIII antibody may therefore be tied to
antiﬁbrinolytic mechanisms and clot protection rather than clot
formation and inﬂuenced by substrates sensitive to variations in
thrombin generation, such as TAFI. Indeed, the anti-FVIII antibody
dose dependently reduced thrombin generation inmouse plasma
ex vivo, whereas TAFI activation and clot lysis acceleration were
considerably less affected by the anti-FVIII antibody.
TAFI gene deﬁciency increased joint bleeding substantially in
aHA, such that it was indistinguishable from that in congenital
HA mice. This implies that TAFI protects from severe joint
bleeding in aHA and suggests that joint bleeding in congenital
hemophilia might be exacerbated by defective TAFI activation.
Indeed, more than a decade of in vitro studies have demon-
strated that TAFI activation is defective in hemophilia plasma,
but in vivo evidence is lacking.14,15,21,49 Here, we demonstrate
that TAFI activation in vivo was signiﬁcantly impaired after joint
injury in congenital FVIII deﬁciency but not in aHA. Therefore,
TAFIa is a modiﬁer of phenotypic joint bleeding in hemophilia,
with the degree of TAFI activation inversely correlating with the
severity of bleeding after joint injury.
The defective activation of TAFI in FVIII2/2mice after joint injury
provides important novel insights into the physiological acti-
vation mechanism of TAFI in vivo. Thrombomodulin enhances
TAFI activation by thrombin .1000-fold and overcomes the
need for FXIa-mediated intrinsic pathway ampliﬁcation to
generate sufﬁcient thrombin for TAFI activation. Therefore,
thrombin-thrombomodulin has often been portrayed as the
physiological activation mechanism for TAFI in vivo.31 In the
hemophilic joint, however, inhibition of TAFI activation by
the activation pathway–selective antibody (MA-TCK26D6)34,35
suggests that thrombin-mediated TAFI activation was the rele-
vant hemostatic mechanism after joint injury, independent of
thrombomodulin despite its reported relative abundance on
synoviocytes.23,50
Table 1. Mortality rate, proportion of deaths, and Hct at
24 h after tail resection
Mortality rate,
% (n/total) P* Hct, %
WT 0 (0/12) 38 6 7
TAFI2/2 0 (0/12) ns 37 6 7
FVIII2/2 50 (4/8) ,.01 19 6 1
WT 1 anti-FVIII 33 (4/12) ,.05 20 6 8
TAFI2/2 1 anti-FVIII 33 (4/12) ,.05 18 6 3
ns, not signiﬁcant.
*vs WT.
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Consistent with the upregulation of uPA levels by monocyte
and macrophage recruitment after joint injury in FVIII2/2 mice,
inhibition of uPA corrected the loss of TAFIa-dependent joint
bleeding protection in aHA TAFI2/2 mice. In addition, TAFIa
mediates a host of antiinﬂammatory activities by modulating
proinﬂammatory mediators, such as C3a, C5a, bradykinin, and
others, and is speciﬁcally beneﬁcial in dampening chronic in-
ﬂammation associated with joint diseases, such as rheumatoid
and osteoarthritis.51,52 Furthermore, the TAFI activation defect
in hemophilia and resulting inability of TAFIa to moderate the
chemoattractant activity of C5a may facilitate the recruitment
of uPA-secreting inﬂammatory cells to the injured joints, further
aggravating bleeding. Thus, the difference in joint bleeding
susceptibility between acquired and congenital hemophilia
provides an emerging concept that assigns a critical role to
uPA-induced bleeding controlled by TAFIa. In congenital
FVIII deﬁciency, the ﬁbrinolytic response continues unchecked
because of severely defective TAFI activation, resulting in
aggravated bleeding. Partial activation of TAFI in aHA provides
a sufﬁciently strong brake on uPA-induced activation of ﬁbri-
nolysis, thereby lowering the susceptibility of joint bleeding
in aHA.
In comparing the tail transection and joint injury bleeding
models, clear differences were found in the mechanisms re-
sponsible for severe bleeding. The diverging bleeding patterns
in the presence of a uPA inhibitor or TXA revealed that the
plasminogen activator involved in bleeding was vascular bed
speciﬁc, delineating bleeding in the joint to be primarily driven
by uPA and tail bleeding by tPA. Although TXA may also have
other effects, the involvement of tPA in tail bleeding is based on
the interpretation that TXA primarily inhibits tPA-mediated ﬁ-
brinolysis. Therefore, differences in joint vs tail bleeding origi-
nate in part from vascular bed–speciﬁc ﬁbrinolysis.
However, the different plasminogen activating mechanisms do
not explain why aHA WT mice were protected against joint
bleeding but not against tail bleeding. Vascular bed–speciﬁc
contributions of endogenous TAFI also take part in the
mechanistic divide between joint and tail bleeding. This is
evidenced by the fact that the endogenous TAFI system
protected the joint against bleeding after injury in WT aHA
mice but did not convey bleed protection after tail transection,
in agreement with previous reports.41,42 However, adminis-
tration of exogenous recombinant TAFI could signiﬁcantly
reduce tail bleeding in FVIII2/2 mice, suggesting that tPA-
mediated ﬁbrinolysis in the tail vasculature contributes to
bleeding.53 Additionally, the lack of a hemostatic effect in the
tail vasculature by endogenous TAFI indicates that TAFIa is not
sufﬁciently generated to overcome the threshold level to exert
its antiﬁbrinolytic effect and protect against tail bleeding
(Figure 7).
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Figure 6. Differential effects of antiﬁbrinolytic drugs
on joint vs tail bleeding. Joint bleeding after knee injury
in FVIII2/2 BALB/c mice (n 5 9-14) (A) or anti-FVIII antibody–
treated (0.25 mg/kg) WT C57Bl/6J or TAFI2/2 C57Bl/6J
mice (n 5 9-15) (B) upon treatment with recombinant
human FVIII (rhFVIII; 200 IU/kg), TXA, amiloride, or anti-
uPA antibody (10 mg/kg). Bleeding was determined by
measuring Hct at day 2 (D2) postinjury. (C) Tail bleeding in
FVIII2/2 BALB/c mice (n5 4-12) upon treatment with rhFVIII
(200 IU/kg), TXA, or anti-uPA antibody (10 mg/kg). Bleeding
was determined by measuring the mouse weight-normalized
blood loss (mL/g) after tail resection for 20 minutes. (D)
Bleeding determined by Hct at 24 hours after tail resection
in FVIII2 /2 BALB/c mice (n 5 4-12) upon treatment with
rhFVIII (200 IU/kg), TXA, or anti-uPA antibody (10 mg/kg).
Kruskal-Wallis test was used followed by Dunn’s post hoc
multiple comparison test to compare experimental mice.
*P , .05, **P , .01, ****P , .0001. ns, not signiﬁcant.
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The protection of TAFI against bleeding and the proﬁ-
brinolytic mechanisms that contribute to bleeding in hemo-
philia were found to be vascular bed-speciﬁc, thereby giving
credence to the term vascular bed–speciﬁc bleeding in ex-
tension of the paradigm vascular bed–speciﬁc thrombosis.
Appreciation of mechanistic differences in vascular bed–
speciﬁc bleeding is key for designing improved antibleeding
strategies for hemophilia but may also help with the in-
terpretation of the effectiveness of current therapies. For in-
stance, TXA is effectively used to reduce surgery-induced
bleeding in nonhemophilia patients after joint replacement,
presumably because of large-vessel bleeding associated with
surgery. In contrast, its efﬁcacy in hemophilic joint bleeding,
presumably caused by synovial microvessel bleeding, remains
elusive.54,55 However, TXA is effective as adjuvant treatment
to clotting factor (or bypassing agent) against mucosal
bleeding or dental extractions.54,55 In this regard, it is im-
portant to note that in contrast to inhibition of tPA-mediated
ﬁbrinolysis, TXA promotes uPA-mediated plasminogen acti-
vation, and TXA has been reported to worsen delayed in-
tracranial hemorrhaging after mouse traumatic brain injury,
which has been attributed to the shift from tPA- to uPA-
mediated ﬁbrinolysis.11,43,44,56
In summary, this study unmasked a prominent role for endog-
enous TAFI in the protection of the vascular bed of the joint
against bleeding that is at least in part responsible for the no-
tably milder phenotypic joint bleeding in aHA compared with
congenital HA. This protective mechanism is dysfunctional in
congenital HA mice because of the inherent defect in thrombin
generation that is required for the activation of TAFI in the joint.
Therefore, clot protection strategies that restore TAFI activation
are important to blunt the susceptibility of the hemophilic joint to
bleeding.
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Figure 7. Proposedmechanismof vascular bed–speciﬁc bleeding in aHA vs congenital HA. The congenital HAmouse is characterized by excessive tail and joint bleeding. In
contrast, the aHA mouse featured a divergent bleeding phenotype existing of excessive tail bleeding but mild joint bleeding. Therefore, the divergent bleeding was vascular
bed speciﬁc, encompassing different ﬁbrinolytic mechanisms. (A) Endogenous TAFI did not control tail bleeding in either aHA or congenital HA mice, because tail bleeding in
aHA was not exacerbated by TAFI gene deﬁciency. In contrast, antiﬁbrinolytic treatment with exogenous TAFI53 or TXA was able to restore hemostasis after tail resection,
suggesting that tPA-driven hyperﬁbrinolysis contributed to hemophilic tail bleeding. (B) In the joints, the extent of bleeding diverged between aHA (minimal bleeding) vs
congenital HA (excessive bleeding), and this difference in bleeding severity was due to the extent of TAFI activation. Residual thrombin formation in aHA provided adequate
TAFI activation for bleed protection, but the defective TAFI activation in congenital HA was not associated with bleed protection and instead contributed to severe bleeding.
Hemophilic joint bleeding was primarily mediated by uPA and largely unresponsive to treatment with TXA, in contrast to hemophilic tail bleeding. (C-D) Primary mechanisms
responsible for achieving hemostasis (coagulation vs antiﬁbrinolysis by TAFIa) for each type of bleeding (tail vs joint) depending on the level of FVIII (or the inverse anti-FVIII
antibody level). (C) No differences were observed in the extent of tail bleeding between congenital HA (FVIII2/2) and aHAWTmice (even when treated at a low dose of anti-FVIII
antibody). (D) In contrast, joint bleeding in aHAWTmice wasminimal but became severe upon elimination of TAFI. Moreover, aHA TAFI2/2mice and congenital HAmice bled to
the same extent after joint injury. Therefore, the hemostasis gap between aHA and congenital HA in the joint was due to adequate vs defective activation of TAFI, respectively.
This indicated that residual thrombin generation in aHA was insufﬁcient to induce functional coagulation to arrest bleeding but proﬁcient to activate TAFI and achieve
hemostasis in the joints. This study points to an important modifying role for TAFI in joint bleeding in hemophilia.
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